Juan Carlos Oliva-Posada
Hospital General de México
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Juan Carlos Oliva-Posada.
Gaceta Mexicana de Oncolog�a | 2017
Alfonso Torres-Lobatón; Eduardo Carrillo-Nolasco; Juan Carlos Oliva-Posada; Rosalva Barra-Martínez; Miguel Ángel Morales-Palomares; Fred Morgan-Ortiz
Introduction: Advanced cervical cancer still represents a major health problem in our country. The percentage diagnosed in young women has been increasing. Objective: We present our institutional experience with conventional therapy in menstruating patients with advanced cervical cancer (stages IB2-IIB); adding in selected cases complementary or rescue surgery as indicated, and our proposal for alternative surgical management for these patients. Methods: We analyzed the cases attended in the Oncology Service, at Hospital General de PALABRAS CLAVE Cáncer cervicouterino pacientes jóvenes
Gaceta Mexicana de Oncolog�a | 2017
Alfonso Torres-Lobatón; Eduardo Carrillo-Nolasco; Juan Carlos Oliva-Posada; Rosalva Barra-Martínez; Miguel Ángel Morales-Palomares; Fred Morgan-Ortiz
Introduction: Advanced cervical cancer (CC) remains a major health problem in our country, with an increasing percentage being diagnosed in young women. Objective: The objective of this study is to present an institutional experience with standard treatment in menstruating women with CC at stages IB2 and IIB, with complementary or rescue surgery being added in selected cases, as well as to propose some management alternatives for these patients. Materials and methods: Analysis of the cases of 45-year-old or younger stage IB2-IIB CC patients who received concomitant chemotherapy and radiotherapy with or without further surgery at the Oncology Department of the Hospital General de México. Results: Ninety-eight patients with a mean age of 37.1 years were treated. In 89 patients, there was follow-up data available, of which 63 (70.7%) had an average evolution of 30 months with no evidence of disease: 12/19 (63.1%) were at stage IB2 and 51/70 (72.8%) at stage II (p > 05). At stage IB2, only 4/8 adenocarcinomas (50%) had these results versus 8/11 (72.7%) squamous cell carcinomas (p > 05). At stage II, the figures were 8/11 for adenocarcinomas (72.7%) and 43/59 for squamous cell carcinomas (72.8%). With further surgery, the results were increased by 10.1%. Failure of established therapeutics was demonstrated in 17 patients (19.3%): 4 cases due to locoregional progression (23.5%) and 13 (76.4%) due to distant dissemination. Conclusions: The results for stage IB2 were inferior to those for stages II, with most failures being related to distant metastasis. To prevent early menopause, exploring the use of neoadjuvant chemotherapy plus radical hysterectomy is recommended in younger patients. (creativecommons.org/ licenses/by-nc-nd/4.0/).
Gaceta Mexicana de Oncología | 2009
F Castillo-Pinto; D Soria-Céspedes; Alfonso Torres-Lobatón; H Cruz-Ortiz; Miguel Ángel Morales-Palomares; e Gutiérrez-Díaz-Ceballos; Juan Carlos Oliva-Posada; Ventura-Molina
Gaceta Mexicana de Oncolog�a | 2018
Dolores Gallardo-Rincón; Eva Ruvalcaba-Limón; Araceli Silva-García; Carlos Eduardo Aranda-Flores; Odilón Félix Quijano-Castro; Joel Bañuelos-Flores; Gonzalo Montalvo-Esquivel; Milagros Clementina Pérez-Quintanilla; Antonio Bahena-González; Gabriela Alamilla-García; Raquel Espinosa-Romero; Rosa María Alvarez-Gomez; Óscar Joel Carrillo-Garibaldi; David Cantú de León; Guillermo Herbert-Núñez; Luz María Hinojosa-García; Miguel Ángel Morales-Palomares; Francisco Javier Ochoa-Carrillo; Luis F. Oñate-Ocaña; Juan Carlos Oliva-Posada; Rosa María Salcedo-Hernández; Antonio Maffuz-Aziz; David Isla-Ortiz; Juan Manuel Medina-Castro; Agustín Güemes-Meza; Amelia Rodríguez-Trejo; Enrique Ávila-Monteverde; Adán Tabarez-Ortiz; Rosa A. Salcedo-Hernández; Sarish del Real-Ordóñez
Archive | 2016
Alfonso Torres-Lobatón; Carlos Lara-Gutiérrez; Juan Carlos Oliva-Posada; Alfonso Torres-Rojo; Edgar Román-Bassaure; Miguel Ángel Morales-Palomares; Dimas Hernández-Aten; Fred Mor
Archive | 2013
Alfonso Torres-Lobatón; Gabriela Cifuentes; Juan Carlos Oliva-Posada; Alfonso Torres-Rojo
Gaceta Mexicana de Oncología | 2011
Alfonso Torres-Lobatón; Carlos Lara-Gutiérrez; Juan Carlos Oliva-Posada; Alfonso Torres-Rojo; Edgar Román-Bassaure; Miguel Ángel Morales-Palomares; Dimas Hernández-Aten; Fred Morgan-Ortiz
Revista Médica del Hospital General de México | 2010
Alfonso Torres-Lobatón; Carlos Lara-Gutiérrez; Juan Carlos Oliva-Posada; Alfonso Torres-Rojo; Edgar Román-Bassaure; Miguel Ángel Morales-Palomares; Dimas Hernández-Aten; Fred Morgan Ortiz
Gaceta Mexicana de Oncología | 2010
Alfonso Torres-Lobatón; Lucía Sarai Alvarado-Vázquez; Edgar Román-Bassaure; Alfonso Torres-Rojo; Fred Morgan-Ortiz; Juan Carlos Oliva-Posada; Miguel Ángel Morales-Palomares
Gaceta Mexicana de Oncología | 2009
Alfonso Torres-Lobatón; Carlos Lara-Gutiérrez; Edgar Román-Bassaure; Juan Carlos Oliva-Posada; Alfonso Torres-Rojo; Miguel Ángel Morales-Palomares; Fred Morgan-Ortiz